• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

FDA approves Novartis’ Promacta for treating infants with severe ITP

August 25, 2015 By Adrienne Dean

FDA approves Novartis’ Promacta for treating infants with severe ITP

Dr. Richard Pazdur of the FDA says, "This new use [of Promacta] in ages one and up builds on a recent approval for ages six years and up, and fills an unmet need for young children whose disease has progressed after use of other available treatments."

The FDA has recently expanded its approval of the blood-platelet-boosting drug Promacta. Now doctors can prescribe the drug to children as young as one year, who have not responded to other medications or surgery.

Promacta is used to treat patients suffering from a rare blood disorder known as chronic Immune Thrombocytopenic Purpura (ITP). Those suffering from ITP have abnormally low platelet counts, which can lead to bleeding under the skin,  in the mucous membranes, or other parts of the body.

“Today’s approval of Promacta emphasizes the FDA’s commitment to fully developing treatments in areas of pediatric hematology and oncology,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“This new use in ages one and up builds on a recent approval for ages six years and up, and fills an unmet need for young children whose disease has progressed after use of other available treatments.”

The expanded approval follows two double-blind, placebo-controlled trials of 159 participants, where researchers were looking for an increase in platelet count.

The first trial included 67 participants and lasted seven weeks; participants took Promacta daily. Between weeks 1 and 6, 62% of participants taking Promacta had increased platelet counts, compared to only 32% of the placebo ground. The second trial involved 92 patients and involved daily administration of Promacta over the course of 13 weeks. Here, 41% of those taking Promacta have increased platelet counts for at least a portion of the 13-week period, compared to 3% of those receiving placebo.

The FDA cautions that Promacta should only be prescribed to patients with ITP who are at risk for the types of internal bleeding described above.

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Science

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • NASA’s InSight spacecraft makes important course correction May 26, 2018
  • Scientists outraged at latest Trump decision May 15, 2018
  • Huge uproar erupts over major incident at Utah park May 13, 2018
  • Incredible moon discovery stuns scientists May 12, 2018
  • Authorities shocked by discovery about common painkiller May 6, 2018
  • Outrageous crocodile experiment stuns scientists May 5, 2018
  • Great Barrier Reef is too quiet, scientists say May 1, 2018
  • Massive Hiroshima bomb discovery shocks scientists May 1, 2018
  • Earth will be slammed by massive asteroid April 29, 2018
  • Teens are doing something incredibly alarming in schools April 29, 2018
  • Huge discovery in Tasmania stuns scientists April 28, 2018
  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018

Copyright © 2022 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress